Lianfang Li

127 Dongming Road
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer.

Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer.

Journal: BMC cancer

Published: December 02, 2025

Reclassifying contralateral axillary metastasis: survival benefit of aggressive local therapy challenges stage IV designation.

Reclassifying contralateral axillary metastasis: survival benefit of aggressive local therapy challenges stage IV designation.

Journal: Frontiers in oncology

Published: November 18, 2025

(Neo)adjuvant therapy patterns and outcomes in patients with HR+/HER2+ early breast cancer: a real-world study using the national cancer information database in China.

(Neo)adjuvant therapy patterns and outcomes in patients with HR+/HER2+ early breast cancer: a real-world study using the national cancer information database in China.

Journal: Therapeutic advances in medical oncology

Published: October 17, 2025

Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis.

Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis.

Journal: Scientific reports

Published: July 16, 2025

Tumor site, stage, and receptor-specific efficacy of radiation therapy in Asian breast cancer patients aged 60 years and older: A SEER database survival analysis incorporating clinicopathological features and nomograms.

Tumor site, stage, and receptor-specific efficacy of radiation therapy in Asian breast cancer patients aged 60 years and older: A SEER database survival analysis incorporating clinicopathological features and nomograms.

Journal: Breast (Edinburgh, Scotland)

Published: April 02, 2025

Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.

Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 24, 2025

A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer.

A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer.

Journal: BMC cancer

Published: March 06, 2024

Targeted axillary dissection after neoadjuvant chemotherapy for highly selective patients with initial cN1 breast cancer: A single-center prospective trial.

Targeted axillary dissection after neoadjuvant chemotherapy for highly selective patients with initial cN1 breast cancer: A single-center prospective trial.

Journal: Chinese medical journal

Published: November 20, 2023

A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy.

A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: July 16, 2023

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial.

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial.

Journal: Nature communications

Published: March 11, 2023

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment-a retrospective cohort study.

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment-a retrospective cohort study.

Journal: Gland surgery

Published: September 20, 2022

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen.

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen.

Journal: Cancers

Published: July 17, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026